Company Description
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada.
Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.
Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
| Country | Canada |
| Founded | 1996 |
| IPO Date | Nov 5, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 259 |
| CEO | Ian C. Mortimer C.M.A., CPA, M.B.A. |
Contact Details
Address: 200 - 3650 Gilmore Way Burnaby, A1 V5G 48W British Columbia, Canada | |
| Phone | (604) 484-3300 |
| Website | xenon-pharma.com |
Stock Details
| Ticker Symbol | XENE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001582313 |
| CUSIP Number | 98420N105 |
| ISIN Number | CA98420N1050 |
| Employer ID | 98-0661854 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ian C. Mortimer C.M.A., CPA, M.B.A. | President, Chief Executive Officer and Director |
| Sherry Aulin | Chief Financial Officer |
| Andrea DiFabio J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. | Chief Commercial Officer |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer |
| Shelley McCloskey B.A. | Executive Vice President of Human Resources |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy and Innovation |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery |
| Sheila M. Grant M.B.A., M.Sc., MBA | Executive Vice President of Research & Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 12, 2024 | 144 | Filing |
| Jun 12, 2024 | 144 | Filing |
| Jun 5, 2024 | 144 | Filing |
| Jun 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 5, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 19, 2024 | 8-K | Current Report |